EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes

Urna Kansakar, Stanislovas S Jankauskas, Shivangi Pande, Pasquale Mone, Fahimeh Varzideh, Gaetano Santulli iD

International Journal of Molecular Sciences · 30.01.2026 · 27 (3) · 1409

DOI: 10.3390/ijms27031409 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.01.2026. Verfasst von Urna Kansakar und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, City University of New York, Manhattan, NY 10031, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health (NIH): National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, American Heart Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orforglipron (LY3502970) is a novel, orally available, nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed to replicate the efficacy of injectable GLP-1 RAs for glycemic control and weight reduction while improving convenience and adherence. Preclinical studies have demonstrated potent receptor engagement, favorable pharmacokinetics, and central nervous system activity. Phase 1–3 clinical trials have shown significant reductions in glycated hemoglobin (HbA1c), fasting and postprandial glucose, body weight, and cardiovascular risk biomarkers, with an acceptable safety profile. This comprehensive review integrates pharmacological, clinical, and mechanistic evidence, critically evaluates the data, identifies knowledge gaps, and outlines future directions for orforglipron in the treatment of type 2 diabetes and obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansAnimalsAdministration, OralOxadiazolesFluorine Compounds

Stichwörter der Autor:innen

GLP-1cardiologydiabetes mellitusmetabolismobesityorforglipron

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsorforglipronOxadiazolesFluorine Compounds

Autor:innen und Institutionen

  • School of Medicine, City University of New York, Manhattan, NY 10031, USA.
  • Casa di Cura "Clinica Montevergine", 83013 Mercogliano, Italy.

ORCID-Profile: Gaetano Santulli

Förderung

  • National Institutes of Health (NIH): National Heart, Lung, and Blood Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • American Heart Association
  • AHA
  • NIH

Zitieren

APA

Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026). Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. International Journal of Molecular Sciences, 27(3), 1409. https://doi.org/10.3390/ijms27031409

Vancouver

Kansakar U, Jankauskas SS, Pande S, Mone P, Varzideh F, Santulli G. Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. International Journal of Molecular Sciences. 2026;27(3):1409. doi:10.3390/ijms27031409

BibTeX
@article{Kansakar2026,
  author = {Kansakar, Urna and Jankauskas, Stanislovas S and Pande, Shivangi and Mone, Pasquale and Varzideh, Fahimeh and Santulli, Gaetano},
  title = {Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {3},
  pages = {1409},
  doi = {10.3390/ijms27031409}
}
Kostenlos starten →